Team:MIT

From 2014.igem.org

(Difference between revisions)
Line 28: Line 28:
</tr>
</tr>
<tr>
<tr>
-
<td width=33.3%><p style="font-size:12.5px; color:purple" align=top><b> NEURODEGENERATIVE <br>DISEASE </b></p></td>
+
<td width=33.3%><p style="font-size:12.5px; color:teal" align=top><b><i> NEURODEGENERATIVE <br>DISEASE </i></b></p></td>
-
<td width=33.3%><p style="font-size:12.5px; color:teal"><b> 6th LEADING CAUSE OF<br> DEATH IN THE U.S.</b></p></td>
+
<td width=33.3%><p style="font-size:12.5px; color:teal"><b><i> 6th LEADING CAUSE OF<br> DEATH IN THE U.S.</b></i></p></td>
<td width=33.3%><p style="font-size:12.5px; color:teal"><i><b> CURRENT DIAGNOSTICS AND<br> THERAPEUTICS ARE INEFFECTIVE</b></i></p></td>
<td width=33.3%><p style="font-size:12.5px; color:teal"><i><b> CURRENT DIAGNOSTICS AND<br> THERAPEUTICS ARE INEFFECTIVE</b></i></p></td>
</tr>
</tr>

Revision as of 20:00, 17 October 2014

 


Image Map



IMPROVING THE DIAGNOSIS AND TREATMENT OF

ALZHEIMER'S DISEASE


NEURODEGENERATIVE
DISEASE

6th LEADING CAUSE OF
DEATH IN THE U.S.

CURRENT DIAGNOSTICS AND
THERAPEUTICS ARE INEFFECTIVE


Alzheimer's disease is the sixth leading cause of death in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. MIT iGEM 2014 is working to change this situation. We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that detects molecular biomarkers for Alzheimer's disease and alters the levels of key enzymes in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.





DETECTION


NATIVE β-AMYLOID RECEPTOR


ENGINEERED B-CELL RECEPTOR


miRNA DETECTION


TREATMENT

DELIVERY

REGULATING β-AMYLOID PRODUCTION
AND DEGRADATION

DELIVERING THE CIRCUIT